# DX-8951f in Treating Patients With Biliary Cancer

> **NCT00005938** · PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo**

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Liver Cancer

## Interventions

- **DRUG:** exatecan mesylate

## Key facts

- **NCT ID:** NCT00005938
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** — (—)
- **Last updated:** 2012-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005938, "DX-8951f in Treating Patients With Biliary Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00005938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*